CEACAM5 and neoplasm: In the MC38-CEA colon carcinoma model, we observed a significant reduction in tumor volumes in the cohort treated with αTIGIT + bintrafusp alfa in comparison to untreated animals, or cohorts that receive either molecule as monotherapy (Figure 2b), as well as an increase in median survival (Figure 2c).